Integer Holdings barely moved in regular trading, with the stock edging up 0.06% to close at $126.59, yet the fresh Q3 2026 numbers tell a much tighter story beneath that calm surface. Net income from ongoing operations landed at $14.98 million on $449.66 million of sales, which puts the focus squarely on earnings power rather than headline growth.
For anyone thinking beyond this week, the bigger tension now sits between that modest quarterly profit line and a rich 41.5x P/E, along with the forecast earnings growth that underpins the long term case for the medical device manufacturer.
Love Integer Holdings' medical device exposure and earnings focus but uneasy about paying a rich 41.5x P/E for a modest profit line? Take a look at our list of stocks that pair steadier earnings power with stronger balance sheets in the list of solid balance sheet and fundamentals stocks (25 results)
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):US$449.66 million vs. US$467.69 million (lower top line compared with the prior period)
-
Net Income from Continuing Operations (Q3 2026 vs. Q3 2025):US$14.98 million vs. US$39.68 million (reduced profit from ongoing operations)
-
Basic EPS (Q3 2026 vs. Q3 2025):US$0.44 vs. US$1.13 (earnings per share declined year on year)
-
Net Profit Margin (Trailing 12 Months vs. Prior Year):5.7% vs. 4.8% (profitability ratio improved over the past year)
Earnings only tell part of Integer Holdings' story, because cash generation often drives what long term investors are really willing to pay for a business. Looking at Integer Holdings' cash flows in isolation, the stock could be a whopping 34% undervalued .
Integer pipeline ambition meets softer Q3 print
The bullish story hinges on Integer Holdings turning a swelling development queue into higher quality production work and better profitability.
"The main thing that has to go right is that Integer Holdings converts its larger pipeline in electrophysiology, structural heart, neurovascular and neuromodulation into launched programs that offset current guidance cuts and inventory adjustments, while restoring margins closer to prior targets through the Integer Production System and scale efficiencies."
Q3 2026 results push back on that timeline. Revenue and net income from continuing operations both fell year on year. Basic EPS dropped to US$0.44. Margin pressure and softer cardio and vascular revenue indicate that the pipeline is not yet offsetting guidance cuts or prior demand air pockets.
Integer risk narrative aligns with Q3 volatility
Bears worry that timing swings, weaker launches and margin sensitivity are not one off issues but a recurring pattern for Integer Holdings.
"The earlier concern that some quarterly strength reflected timing shifts and inventory pull forward rather than underlying demand now connects to the cuts to 2026 guidance and the 3% to 4% growth headwind from underperforming new products."
Q3 2026 numbers give that concern more weight. Sales declined compared with Q3 2025 and net income from continuing operations more than halved. Management has withdrawn 2026 guidance during the go private process, so investors now lack a formal growth roadmap to counter the idea of ongoing demand air pockets.
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all .
Hunt For Underpriced Earnings Power
Integer Holdings reported a softer quarter that raises questions about the pace of margin recovery. The real opportunity sits in stocks that could be undervalued before the market closes that gap.
-
Company 1 - 38% below our estimate - targets coconut based drinks moving from niche shelves to everyday baskets across retail and foodservice channels.
-
Company 2 - 27% below our estimate - sells diagnostic and test equipment that utilities adopt as they upgrade aging grids for electrification and reliability.
-
Company 3 - 22% below our estimate - expands electrical contracting capacity to capture hyperscale data center build outs as customers rush to add power and connectivity.
That is three of the list. See the full list of 29 companies trading below our fair value estimates →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ITGR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
